UKUK

British and Serbian scientists look into freezing genes

24.07.2009

Novi Sad/London - EU-funded researchers have identified the genes that allow insects called Arctic springtails to survive temperatures as low as -14°C. 'This is the first in-depth molecular study on the underlying cold survival mechanisms in this species,' commented Melody Clark of the British Antarctic Survey, the lead author of the article. 'Such information is not only of interest to ecologists, but also to the medical field of cryobiology.'
Many species of springtail can survive low temperatures; most achieve this by using the 'freeze avoidance' technique, and some use freeze tolerance. However, the Arctic springtail, Megaphorura arctica, uses a third, rarer technique known as cryoprotective dehydration. As temperatures fall, these tiny creatures dehydrate themselves, taking on the appearance of shrivelled husks in the process. When the weather becomes more clement, the insects rehydrate themselves and resume their normal activities.
The study, published in the journal BMC Genomics (Vol. 10, 2009) was supported in part by the SLEEPING BEAUTY ('Dormancy of cells and organisms-strategies for survival and preservation') project, which is funded under the 'New and Emerging Science and Technology' (NEST) activity area of the Sixth Framework Programme (FP6).
In this study, researchers from the British Antarctic Survey and the University of Novi Sad in Serbia teamed up to identify the genes controlling the processes of dehydration and rehydration. Their analyses revealed that a wide range of genes become active as temperatures fall, including genes controlling the production of a natural antifreeze called trehalose as well as genes involved in tissue and cell remodelling.
When temperatures rise and the springtail recovers, genes involved in energy production, tissue repair and cell division are activated. The findings could have important implications for those working on techniques for preserving cells and tissues at low temperatures for long periods, for example in biobanks.
According to Europe's biobanking project BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), there are currently 300,000+ samples of whole blood, 1.7m of serum, 1.1m of plasma, 8m of FFPE tissue, and 0.5m cryo-conserved samples stored in the 300 EU biobanks.

UKUK

24.11.2011

London – The European Medicines Agency has recalled all batches of the cancer drugs Busilvex, Velcade and Vidaza manufactured at Boehringer Ingelheim’s Ben Venue Laboratories facility in Bedford, Ohio, from the European market....

UKUK

14.11.2011

London – GlaxoSmithKline goes west. The British pharmaceutical company launched the $50-million GSK Canada Life Sciences Innovation Fund that will invest in “early-stage breakthrough research” in health care life science in...

UKUK

04.10.2011

Heidelberg/Cambridge/London– A team of researchers from GlaxoSmithKline, the biotech company Cellzome and from Universities Cambridge, Ulm and Amsterdam have found a promising treatment for mixed lineage (MLL-fusion) leukaemia...

UKUK

01.10.2011

Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for...

UKUK

01.10.2011

Wolverhampton – One of the challenges for manufacturers of probiotic foods is getting large enough numbers of the bacteria into the intestines; most perish under the strongly acidic conditions in the stomach. Scientists from the...

UKUK

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based...

UKUK

26.09.2011

London – The first clinical trial using human embryonic stem cells will be carried out at the Moorfields Eye hospital in London. Doctors will inject retinal cells into the eyes of 12 patients with Stargardt‘s macular dystrophy, a...

UKUK

20.09.2011

Amersham – GE Healthcare intends to stay a major force in cancer. The health business of the US-technological company, which is based in London, announced to reserve €730m of its total R&D budget over the next five years for...

UKUK

29.08.2011

Cambridge - A new biotech spin off from the University of Cambridge launched with €6.8m venture capital. Newco Mission Therapeutics Ltd. plans to develop cancer drugs targeting enzymes in ubiquitin pathways that control cellular...

Displaying results 21 to 30 out of 396

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/2/article/british-and-serbian-scientists-look-into-freezing-genes.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014


Current issue

All issues

Product of the week

Products